Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?

Cancer Immunology, Immunotherapy

Volumn 65, Issue 5, 2016, Pages 493-497

  Weigelin, Bettina ^a   Bolaños, Elixabet ^b   Rodriguez Ruiz, Maria E ^b   Martinez Forero, Ivan ^b   Friedl, Peter ^a   Melero, Ignacio ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Adoptive T cell transfer; CARTs; CD137 (4 1BB); Combined immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CD137 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; PF 05082566; UNCLASSIFIED DRUG; URELUMAB;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL THERAPY; CLINICAL TRIAL (TOPIC); CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; ENDOTHELIUM CELL; HUMAN; INTRAVITAL MICROSCOPY; MELANOMA B16; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL CULTURE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MODELS, IMMUNOLOGICAL; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84960349832     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1818-5     Document Type: Editorial

References (28)

1. Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JL, Haanen J (2015) Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 15:457–472. doi:10.1038/nrc3973
2. Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161:205–214. doi:10.1016/j.cell.2015.03.030
3. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH (2014) Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 32:189–225. doi:10.1146/annurev-immunol-032713-120136
4. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73. doi:10.1126/scitranslmed.3002842
5. Garfall AL, Maus MV, Hwang WT et al (2015) Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 373:1040–1047. doi:10.1056/NEJMoa1504542
6. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34. doi:10.1056/NEJMoa1504030
7. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD (2013) Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 19:1044–1053. doi:10.1158/1078-0432.CCR-12-2065
8. Vinay DS, Kwon BS (2014) 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep. 47:122–129
9. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682–685
10. Morales-Kastresana A, Catalan E, Hervas-Stubbs S, Palazon A, Azpilikueta A, Bolanos E, Anel A, Pardo J, Melero I (2013) Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb. J Immunother Cancer. 1:3. doi:10.1186/2051-1426-1-3
11. Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M et al (2015) Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires Batf3-dependent dendritic cells. Cancer Discov. 6:71–79. doi:10.1158/2159-8290.CD-15-0510
12. So T, Lee SW, Croft M (2008) Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev 19:253–262. doi:10.1016/j.cytogfr.2008.04.003
13. Kim YH, Choi BK, Oh HS, Kang WJ, Mittler RS, Kwon BS (2009) Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther 8:469–478. doi:10.1158/1535-7163.MCT-08-0993
14. Morales-Kastresana A, Sanmamed MF, Rodriguez I et al (2013) Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 19:6151–6162. doi:10.1158/1078-0432.CCR-13-1189
15. May KF Jr, Chen L, Zheng P, Liu Y (2002) Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8 + T cells. Cancer Res 62:3459–3465
16. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I (2010) Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 37:508–516. doi:10.1053/j.seminoncol.2010.09.008
17. Sznol M, Hodi FS, Margolin K, McDermott DF, Ernstoff MS, Kirkwood JM, Wojtaszek C, Feltquate D, Logan T (2008) Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol. 26. Abstract 3007
18. Fisher TS, Kamperschroer C, Oliphant T et al (2012) Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother 61:1721–1733. doi:10.1007/s00262-012-1237-1
19. Gopal AK, Bartlett NL, Levy R et al (2015) A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20 + NHL. J Clin Oncol. 33. Abstract 3004
20. Dubrot J, Milheiro F, Alfaro C et al (2010) Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother 59:1223–1233. doi:10.1007/s00262-010-0846-9
21. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD (2007) Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110:201–210. doi:10.1182/blood-2006-11-056168
22. Gros A, Robbins PF, Yao X et al (2014) PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 124:2246–2259. doi:10.1172/JCI73639
23. Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L (2013) Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS ONE 8:e60031. doi:10.1371/journal.pone.0060031
24. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH (2002) Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20:143–148. doi:10.1038/nbt0202-143
25. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG (2011) Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 34:236–250. doi:10.1097/CJI.0b013e318209e7ec
26. Palazon A, Teijeira A, Martinez-Forero I et al (2011) Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 71:801–811. doi:10.1158/0008-5472.CAN-10-1733
27. Carpenito C, Milone MC, Hassan R et al (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 106:3360–3365. doi:10.1073/pnas.0813101106
28. Weigelin B, Bolanos E, Teijeira A et al (2015) Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proc Natl Acad Sci U S A 112:7551–7556. doi:10.1073/pnas.1506357112